Want to see PMI full AI Analyst Report?
PMI Stock Chart & Stats
$3.86
-$0.03(-27.06%)
At close: 4:00 PM EDT
$3.86
-$0.03(-27.06%)
Day’s Range― - ―
52-Week Range$2.65 - $684.00
Previous CloseN/A
Volume6.87M
Average Volume (3M)3.03M
Market Cap
$10.41M
Enterprise Value$16.71
Total Cash (Recent Filing)$38.00K
Total Debt (Recent Filing)$878.00K
Price to Earnings (P/E)―
Beta-1.90
Next Earnings
Nov 13, 2026EPS Estimate
-1.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-20.46
Shares Outstanding2,338,634
10 Day Avg. Volume148,622
30 Day Avg. Volume3,031,285
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)34.04
Price to Sales (P/S)26.11
P/FCF Ratio-8.23
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-8.5
Revenue Forecast (FY)$5.50M
Bulls Say, Bears Say
Bulls Say
Revenue And Gross-margin ImprovementStronger revenue and gross margin indicate improving commercial traction and unit economics. If sustained, this combination can increase the contribution from each sale, support investment in product development, and create a foundation for eventual operating leverage.
Improved Capital StructureLower leverage and restored positive equity reduce balance-sheet stress compared with prior years. This gives the company a more stable capital base while it pursues growth, although the benefit depends on continued progress toward profitability and reduced cash consumption.
Artificial-heart Platform DevelopmentThe Emperor Total Artificial Heart provides a differentiated development platform aimed at eliminating external pneumatic drivers while preserving surgical placement and pump performance. Patented technology and a multi-year regulatory roadmap could support durable product differentiation if development succeeds.
Bears Say
Severe Ongoing LossesThe company remains far from sustainable earnings despite better revenue and gross margin. Very large operating and net losses indicate that the current cost structure absorbs the benefit of growth, limiting internally funded investment and increasing dependence on future execution.
Material Cash BurnPersistent negative operating and free cash flow means growth is not yet translating into financial self-sufficiency. Continued cash outflows can require external funding, constrain strategic flexibility, and heighten financing risk until operating performance improves materially.
NYSE American Compliance RiskThe accepted compliance plan preserves listing access but confirms significant financial weakness and ongoing regulatory oversight. Quarterly reviews and an 18-month remediation window create continuing execution pressure, while failure to restore compliance could disrupt market access.
Picard Medical, Inc. News
PMI FAQ
What was Picard Medical, Inc.’s price range in the past 12 months?
Picard Medical, Inc. lowest stock price was $2.65 and its highest was $684.00 in the past 12 months.
What is Picard Medical, Inc.’s market cap?
Picard Medical, Inc.’s market cap is $10.41M.
When is Picard Medical, Inc.’s upcoming earnings report date?
Picard Medical, Inc.’s upcoming earnings report date is Nov 13, 2026 which is in 43 days.
How were Picard Medical, Inc.’s earnings last quarter?
Picard Medical, Inc. released its earnings results on Aug 19, 2026. The company reported -$3.05 earnings per share for the quarter, missing the consensus estimate of -$1.5 by -$1.55.
Is Picard Medical, Inc. overvalued?
According to Wall Street analysts Picard Medical, Inc.’s price is currently Overvalued.
Does Picard Medical, Inc. pay dividends?
Picard Medical, Inc. does not currently pay dividends.
What is Picard Medical, Inc.’s EPS estimate?
Picard Medical, Inc.’s EPS estimate is -1.5.
How many shares outstanding does Picard Medical, Inc. have?
Picard Medical, Inc. has 2,338,634 shares outstanding.
What happened to Picard Medical, Inc.’s price movement after its last earnings report?
Picard Medical, Inc. reported an EPS of -$3.05 in its last earnings report, missing expectations of -$1.5. Following the earnings report the stock price went down -7.903%.
Which hedge fund is a major shareholder of Picard Medical, Inc.?
Currently, no hedge funds are holding shares in PMI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Picard Medical, Inc.
Picard Medical, Inc., through its associated companies, is dedicated to the entire process of medical device commercialization, from initial design and manufacturing to production, distribution, marketing, and sales. A key product in its portfolio is the SynCardia TAH, a sophisticated total artificial heart specifically engineered to supplant a failing human heart in individuals afflicted with advanced cardiac disease. The firm's market presence extends across the United States, Europe, and other international regions. Established in 2021, Picard Medical maintains its primary operations in Tucson, Arizona, functioning as a direct subsidiary of Hunniwell Picard I, Llc.
Technical Analysis
Aethlon Medical
―
―
Catheter Precision
―
Heart Test Laboratories, Inc.
―
Autonomix Medical, Inc.
―
Ownership Overview
―
Insiders
4.38% Mutual Funds
― Other Institutional Investors
95.62% Public Companies and
Individual Investors